tirzepatide attenuates mammary tumor progression in diet induced obese mice High-Fat Diet Exposure in Early Life Alters Mammary Metabolic and Inflammatory Microenvironment in Favor of Breast Tumorigenesis Later in Life in Mice Tirzepatide as an innovative treatment
Description
The dose response extends beyond weight loss to metabolic parameters
External resources PMC: Retrospective evaluation of GLP-1 receptor agonists in SLE patients Arthritis and Rheumatology: GLP-1 RA cardiovascular and kidney outcomes in SLE PubMed: Anti-inflammatory effects of tirzepatide systematic review and meta-analysis American College of Rheumatology: 2025 guideline for SLE treatment In case I do not see you, good afternoon, good evening, and good night
First-time prescribing of ADM tirzepatide slightly decreased (-1.4%), while first-time prescribing of AOM tirzepatide (16.4%) increased throughout the quarter

Four RCTs (n = 3,553 participants) met the inclusion criteria

Move from 10 mg to 7.5 mg for 6 weeks, then 7.5 mg to 5 mg for 6 weeks, then 5 mg to 2.5 mg for 6 weeks before complete discontinuation

Using tirzepatide alongside cagrilintide or other peptide stacks